We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Overly busy bankers

10 November 2016 By Robert Cyran

The $217 bln drug company has decided not to split, but is mulling selling or hiving off its consumer health division. There’s no obvious logic for a pharma firm to hawk Advil and ChapStick. Pfizer history suggests it’s a better seller than buyer, and the timing is also right.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)